Boston Trust Walden’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$68.1M Sell
359,256
-19,269
-5% -$2.86M 0.52% 66
2026
Q1
$35.2M Sell
378,525
-49,211
-12% -$4.36M 0.29% 126
2025
Q4
$34.4M Sell
427,736
-32,551
-7% -$2.73M 0.26% 140
2025
Q3
$44.9M Sell
460,287
-385,624
-46% -$31.1M 0.33% 121
2025
Q2
$59M Buy
845,911
+19,579
+2% +$1.12M 0.42% 91
2025
Q1
$41M Buy
826,332
+6,216
+0.8% +$393K 0.3% 132
2024
Q4
$57.3M Buy
820,116
+313,689
+62% +$26.1M 0.4% 89
2024
Q3
$53.1M Buy
+506,427
New +$59.2M 0.37% 107

Other funds holding ACLS

Boston Trust Walden's ACLS Position: Q2 2026 in Review

Boston Trust Walden reduced its Axcelis (ACLS) stake by 5.1% in Q2 2026, selling an estimated $2.86M and leaving 359,256 shares worth $68.1M. The position accounts for 0.52% of the portfolio, ranked #66.

Boston Trust Walden first reported a position in ACLS in Q3 2024 and has held it in 8 quarters since. 110 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • Boston Trust Walden held 359,256 shares of Axcelis worth $68.1M as of Q2 2026.
  • Boston Trust Walden sold 19,269 Axcelis shares in Q2 2026, an estimated $2.86M.
  • Axcelis made up 0.52% of Boston Trust Walden's portfolio in Q2 2026, its #66 holding.
  • Boston Trust Walden first reported a position in Axcelis in Q3 2024 and has held it in 8 quarters since.
  • 110 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.